Regeneron Pharmaceuticals | REGN - Net Income


Regeneron Pharmaceuticals reported $1.3B in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Agenus USD 39.17M 49.8M Mar/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Alnylam Pharmaceuticals USD 2.17B 2B Sep/2026
Amgen USD 2.38B 556M Jun/2026
Astellas Pharma JPY 141.83B 98.31B Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD 44.76M 60.76M Jun/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Eli Lilly USD 7.1B 301M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 1.54B 1.11B Sep/2026
Incyte USD -784.8M 1.37B Sep/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
J&J USD 210M 5.32B Sep/2026
Kyowa Hakko Kirin JPY 18.58B 6.55B Jun/2026
Merck USD 5.07B 6.4B Sep/2026
Moderna USD -1.34B 517M Mar/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Novartis USD 3.26B 108M Jun/2026
Novartis USD 3.16B 747M Mar/2026
Pfizer USD -248M 2.94B Jun/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 1.61B 2.42B Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Teva Pharmaceutical Industries USD -576M 945M Jun/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
United Therapeutics USD 333M 58.1M Jun/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026